Company intelligence / Profile preview

Nitiloop

Ownership: Private
Development stage: NDA

Overview

The NovaCross family of microcatheters developed by Nitiloop are FDA-cleared devices designed to facilitate guidewire placement across complex vascular lesions, including chronic total occlusions. These devices have been integrated into Microbot Medical's portfolio following acquisition in October 2022.

Therapeutic areas: Cardiovascular
Modalities: DeviceMedical device (microcatheter)
Industry: Surgical Medical Devices

Drug pipeline

2 assets

LIBERTY Endovascular Robotic Surgical System

NDA

Indications: Peripheral vascular interventions

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Nitiloop.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nitiloop.

Explore the full profile